Short Bowel Syndrome - Pipeline Review, H1 2018

  • ID: 4576097
  • Report
  • 59 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • Adocia SAS
  • Ardelyx Inc
  • Naia Ltd
  • Nutrinia Ltd
  • OxThera AB
  • Sancilio & Company Inc
  • MORE
Short Bowel Syndrome - Pipeline Review, H1 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Short Bowel Syndrome - Pipeline Review, H1 2018, provides an overview of the Short Bowel Syndrome (Gastrointestinal) pipeline landscape.

Short bowel syndrome is a complex disease that occurs due to the physical loss or the loss of function of a portion of the small and/or large intestine. Symptoms include bloating, cramping, fatigue, heartburn, vomiting, weakness and diarrhea. Complications of short bowel syndrome include malnutrition, peptic ulcers, kidney stones and small intestinal bacterial overgrowth. Treatment includes vitamin and mineral supplements, antibiotics, proton pump inhibitors and bile-salt binders.

Report Highlights:

This latest pipeline guide Short Bowel Syndrome - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Short Bowel Syndrome (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Short Bowel Syndrome (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Short Bowel Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, IND/CTA Filed and Preclinical stages are 2, 2, 2 and 7 respectively.

Short Bowel Syndrome (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Short Bowel Syndrome (Gastrointestinal).
  • The pipeline guide reviews pipeline therapeutics for Short Bowel Syndrome (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Short Bowel Syndrome (Gastrointestinal) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Short Bowel Syndrome (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Short Bowel Syndrome (Gastrointestinal)
Reasons for Purchase:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Short Bowel Syndrome (Gastrointestinal).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Short Bowel Syndrome (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Adocia SAS
  • Ardelyx Inc
  • Naia Ltd
  • Nutrinia Ltd
  • OxThera AB
  • Sancilio & Company Inc
  • MORE
Introduction

Report Coverage

Short Bowel Syndrome - Overview

Short Bowel Syndrome - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Short Bowel Syndrome - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Short Bowel Syndrome - Companies Involved in Therapeutics Development

Adocia SAS

Ardelyx Inc

Hanmi Pharmaceuticals Co Ltd

Naia Ltd

Nutrinia Ltd

OxThera AB

Sancilio & Company Inc

Shire Plc

Tasly Pharmaceutical Group Co Ltd

Zealand Pharma AS

Short Bowel Syndrome - Drug Profiles

exenatide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FE-203799 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

glepaglutide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GXG-8 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HM-15912 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

melatonin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NB-1002 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NTRA-9620 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Oxabact - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RDX-8940 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SC-403 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

teduglutide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

teduglutide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Short Bowel Syndrome - Dormant Projects

Short Bowel Syndrome - Discontinued Products

Short Bowel Syndrome - Product Development Milestones

Featured News & Press Releases

May 31, 2018: Zealand Pharma to present new clinical Phase 2 results on glepaglutide for the treatment of short bowel syndrome at the DDW conference in the U.S.

Apr 26, 2018: Zealand announces successful End-of-Phase 2 meeting with FDA on glepaglutide for short bowel syndrome

Apr 09, 2018: Revestive is accepted for restricted use within NHS Scotland

Jan 23, 2018: New clinical evidence support potential for glepaglutide as a once-weekly drug for short bowel syndrome

Jan 23, 2018: Zealand Pharma to present Phase 2 results on glepaglutide at the ASPEN 2018 Conference in Las Vegas, U.S.

Jan 22, 2018: Shire to Present Data on Short Bowel Syndrome With Intestinal Failure at the ASPEN 2018 Nutrition Science & Practice Conference

Nov 15, 2017: Naia Rare Diseases Announces Clinical Trial Authorization to Initiate Clinical Trials of NB 1001 for Short Bowel Syndrome in the United Kingdom

Nov 14, 2017: Recruitment completed in trial to evaluate the optimal dosing frequency for Zealands long-acting GLP-2 analog glepaglutide

Oct 24, 2017: U.S. FDA Grants Orphan Drug Designation to Glepaglutide for the Treatment of Short Bowel Syndrome

Oct 12, 2017: Zealand has initiated a clinical trial to evaluate the potential for less than once-daily dosing with its long-acting GLP-2 analog glepaglutide

Jun 19, 2017: Glepaglutide meets primary endpoint in Phase 2 trial in patients with short bowel syndrome

Feb 06, 2017: Patient recruitment completed for phase II trial with glepaglutide for treatment of short bowel syndrome

Dec 19, 2016: IND submission to initiate clinical trials of NB 1001 (XTEN-GLP1) for treatment of Short Bowel Syndrome announced by Naia Rare Diseases

Nov 29, 2016: Naia Rare Diseases Announces Investigational New Drug Application Submission to Initiate Clinical Trials of NB 1001 for Short Bowel Syndrome

Jul 07, 2016: Shire Receives Extension of Market Authorization in Europe for Revestive (Teduglutide) for the Treatment of Paediatric Patients with Short Bowel Syndrome (SBS)

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Short Bowel Syndrome, H1 2018

Number of Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Short Bowel Syndrome - Pipeline by Adocia SAS, H1 2018

Short Bowel Syndrome - Pipeline by Ardelyx Inc, H1 2018

Short Bowel Syndrome - Pipeline by Hanmi Pharmaceuticals Co Ltd, H1 2018

Short Bowel Syndrome - Pipeline by Naia Ltd, H1 2018

Short Bowel Syndrome - Pipeline by Nutrinia Ltd, H1 2018

Short Bowel Syndrome - Pipeline by OxThera AB, H1 2018

Short Bowel Syndrome - Pipeline by Sancilio & Company Inc, H1 2018

Short Bowel Syndrome - Pipeline by Shire Plc, H1 2018

Short Bowel Syndrome - Pipeline by Tasly Pharmaceutical Group Co Ltd, H1 2018

Short Bowel Syndrome - Pipeline by Zealand Pharma AS, H1 2018

Short Bowel Syndrome - Dormant Projects, H1 2018

Short Bowel Syndrome - Discontinued Products, H1 2018

List of Figures

Number of Products under Development for Short Bowel Syndrome, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products by Targets, H1 2018

Number of Products by Stage and Targets, H1 2018

Number of Products by Mechanism of Actions, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Adocia SAS
  • Ardelyx Inc
  • Hanmi Pharmaceuticals Co Ltd
  • Naia Ltd
  • Nutrinia Ltd
  • OxThera AB
  • Sancilio & Company Inc
  • Shire Plc
  • Tasly Pharmaceutical Group Co Ltd
  • Zealand Pharma AS
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll